001     164574
005     20230915090554.0
024 7 _ |a pmc:PMC9139373
|2 pmc
024 7 _ |a 10.3390/brainsci12050573
|2 doi
024 7 _ |a pmid:35624960
|2 pmid
037 _ _ |a DZNE-2022-01123
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Scuteri, Damiana
|0 0000-0001-5846-7058
|b 0
245 _ _ |a Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization-Observation-Behavior-Intensity-Dementia (I-MOBID2) Pain Scale: Study Protocol.
260 _ _ |a Basel
|c 2022
|b MDPI AG
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1654779356_6361
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Up to 80% of Alzheimer's disease (AD) patients in nursing homes experiences chronic pain and 97% develops fluctuant neuropsychiatric symptoms (NPS). Agitation, associated with unrelieved pain, is managed through antipsychotics and may increase the risk of death. Evidence is accumulating in favor of analgesia for a safer, effective therapy of agitation. The Italian version of Mobilization-Observation-Behavior-Intensity-Dementia, I-MOBID2, recently validated in the Italian setting, shows: good scale content validity index (0.89), high construct validity (Spearman rank-order correlation Rho = 0.748), reliable internal consistency (Cronbach's α coefficient = 0.751), good-excellent inter-rater (intraclass correlation coefficient, ICC = 0.778) and test-retest (ICC = 0.902) reliability, and good inter-rater and test-retest agreement (Cohen's K = 0.744) with 5.8 min completion time. This study intends to identify the responsiveness of the I-MOBID2 based on COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN) recommendations, assessing the a priori hypotheses of (1) the efficacy of painkillers administered to severe AD patients after proper pain assessment and (2) the effect of reduction of the Cohen-Mansfield Agitation Inventory (CMAI) score and of agitation rescue medications. This protocol is approved by Calabria Region Ethics Committee protocol No. 31/2017 and follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a I-MOBID2
|2 Other
650 _ 7 |a agitation
|2 Other
650 _ 7 |a dementia
|2 Other
650 _ 7 |a pain
|2 Other
650 _ 7 |a responsiveness
|2 Other
700 1 _ |a Contrada, Marianna
|0 0000-0002-9825-1347
|b 1
700 1 _ |a Loria, Teresa
|b 2
700 1 _ |a Tonin, Paolo
|0 0000-0002-4867-1378
|b 3
700 1 _ |a Sandrini, Giorgio
|b 4
700 1 _ |a Tamburin, Stefano
|0 0000-0002-1561-2187
|b 5
700 1 _ |a Nicotera, Pierluigi
|0 P:(DE-2719)2010732
|b 6
|u dzne
700 1 _ |a Bagetta, Giacinto
|0 0000-0001-8540-6218
|b 7
700 1 _ |a Corasaniti, Maria Tiziana
|0 0000-0001-6472-0697
|b 8
773 _ _ |a 10.3390/brainsci12050573
|g Vol. 12, no. 5, p. 573 -
|0 PERI:(DE-600)2651993-8
|n 5
|p 573
|t Brain Sciences
|v 12
|y 2022
|x 2076-3425
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/164574/files/Pharmacological%20Treatment%20of%20Pain%20and%20Agitation%20in%20Severe%20Dementia%20and%20Responsiveness%20to%20Change%20of%20the%20Italian%20Mobilization%E2%80%93Observation%E2%80%93Behavior%E2%80%93Intensity%E2%80%93Dementia%20%28I-MOBID2%29%20Pain%20Scale%3A.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/164574/files/Pharmacological%20Treatment%20of%20Pain%20and%20Agitation%20in%20Severe%20Dementia%20and%20Responsiveness%20to%20Change%20of%20the%20Italian%20Mobilization%E2%80%93Observation%E2%80%93Behavior%E2%80%93Intensity%E2%80%93Dementia%20%28I-MOBID2%29%20Pain%20Scale%3A.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:164574
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2010732
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-09-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-09-15
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-09-15
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-09-15
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-09-15
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN SCI : 2021
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-01-07T14:19:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-01-07T14:19:48Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-01-07T14:19:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-03-30
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-03-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-03-30
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-03-30
920 1 _ |0 I:(DE-2719)1030000
|k Scientific board
|l Scientific board
|x 0
920 1 _ |0 I:(DE-2719)1013003
|k AG Bano
|l Aging and neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1030000
980 _ _ |a I:(DE-2719)1013003
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21